FPAS
TGTX icon

Focus Partners Advisor Solutions’s TG Therapeutics TGTX Stock Holding History

Focus Partners Advisor Solutions’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Buy
+6,261
New +$256K ﹤0.01% 948
2025
Q2 		– Sell
-5,439
Closed -$214K – 1169
2025
Q1 		$214K Buy
+5,439
New +$183K ﹤0.01% 889

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Focus Partners Advisor Solutions's TGTX Position: Q2 2026 in Review

Focus Partners Advisor Solutions opened a new position in TG Therapeutics (TGTX) in Q2 2026: 6,261 shares worth $344K. The stake represents ﹤0.01% of the portfolio and ranks #948 among its holdings. This is a return to the name: Focus Partners Advisor Solutions previously reported a position in TGTX as recently as Q1 2025.

Focus Partners Advisor Solutions first reported a position in TGTX in Q1 2025 and has held it in 2 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Focus Partners Advisor Solutions held 6,261 shares of TG Therapeutics worth $344K as of Q2 2026.
  • TG Therapeutics was a new Focus Partners Advisor Solutions position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #948 holding.
  • Focus Partners Advisor Solutions first reported a position in TG Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.